Featured News
Advance Drug Development with AI-Powered New Approach Methodologies
Safer, smarter drug development with NAMs
In a recent Genetic Engineering & Biotechnology News feature, Julie Frearson, Chief Scientific Officer at Charles River, shares how New Approach Methodologies (NAMs) are helping biopharma companies accelerate innovation while reducing reliance on animal testing.
NAMs, ranging from advanced in vitro cell models to AI-driven predictive systems, offer human-relevant insights that improve productivity and increase the likelihood of therapeutic success. We are leading the way with AI-assisted drug design, virtual control groups, and the Retrogenix® microarray platform, which was recently accepted into the FDA’s Innovative Science and Technology Approaches for New Drugs (ISTAND) Pilot Program.
NAMs can increase a pharma company’s productivity and their chance of success on a therapeutic program, because using human-based assays can theoretically improve your chances that a drug will be safe and efficacious in humans.”
Julie Frearson, SVP, Chief Scientific Officer
Off-Target, On-Point: How Retrogenix Reduces Risk and Animal Use
Learn how the Retrogenix platform is reshaping drug development by identifying off-target risks earlier, reducing animal use, and gaining traction with regulators.
Listen to the Podcast